CN109223746A - A kind of shellac acid is for reversing oophoroma to the purposes of taxol resistance - Google Patents
A kind of shellac acid is for reversing oophoroma to the purposes of taxol resistance Download PDFInfo
- Publication number
- CN109223746A CN109223746A CN201811167944.2A CN201811167944A CN109223746A CN 109223746 A CN109223746 A CN 109223746A CN 201811167944 A CN201811167944 A CN 201811167944A CN 109223746 A CN109223746 A CN 109223746A
- Authority
- CN
- China
- Prior art keywords
- taxol
- oophoroma
- acid
- cell
- resistance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
The invention discloses a kind of shellac acid for reversing oophoroma to the purposes of taxol resistance.Oophoroma is one of big malignant tumour of female reproductive system three, and the time-to-live of most Patients with Advanced Ovarian Carcinoma is no more than 5 years.The clinical clinical treatment of oophoroma is usually using surgical cytoreduction, the postoperative chemotherapy means for being aided with platinum class and taxol.But the drug resistance that ovarian cancer cell generates chemotherapeutics results in this sick high recurrence rate, and the death rate is high, therefore, it has become the bottlenecks of clinical treatment.It is a discovery of the invention that shellac is sour, jalaric acid, cypress acid can enhance Taxol to the inhibited proliferation of A2780/Taxol cell in various degree, cell is improved to Taxol sensibility, can be developed into and reverse oophoroma to the drug of taxol resistance.
Description
Technical field
The invention belongs to field of medicaments, it is related to the discovery for reversing oophoroma to the drug of taxol resistance.
Background technique
Oophoroma is one of big malignant tumour of female reproductive system three, and when the survival of most Patients with Advanced Ovarian Carcinoma
Between be no more than 5 years.The clinical clinical treatment of oophoroma is usually using surgical cytoreduction, postoperative platinum class and the taxol of being aided with
Chemotherapy means.But the drug resistance that ovarian cancer cell generates chemotherapeutics results in this sick high recurrence rate, and the death rate occupies height
Under not, therefore, it has become the bottlenecks of clinical treatment.
Summary of the invention
The purpose of the present invention is to provide for reversing oophoroma to the drug of taxol resistance.
The present invention is achieved through the following technical solutions:
Application of the shellac acid in terms of the drug that preparation reverses ovarian cancer drug-resistant.
Further, reverse oophoroma to taxol resistance.
It is a kind of for reversing the pharmaceutical preparation of ovarian cancer drug-resistant, active constituent is shellac acid.
Further, reverse oophoroma to taxol resistance.
The utility model has the advantages that
It is a discovery of the invention that shellac is sour, jalaric acid, cypress acid can enhance Taxol to A2780/Taxol in various degree
The inhibited proliferation of cell improves cell to Taxol sensibility, can be developed into and reverse oophoroma to the medicine of taxol resistance
Object.
Detailed description of the invention
Fig. 1 is shellac acid, jalaric acid, cypress acid and cedar wood alcohol chemical structural formula；
Fig. 2 is the reverse effect of each compounds on ovarian cancer cell A2780/Taxol drug resistance.
Specific embodiment
Essentiality content of the present invention is specifically introduced below with reference to embodiment, but does not limit protection model of the invention with this
It encloses.
One, experimental material
Shellac acid, jalaric acid, cypress acid and cedar wood alcohol self-control, purity >=98%, structural formula are as shown in Figure 1.It is purple
China fir alcohol (Taxol) is purchased from Xi'an Kang Nuo Chemical Co., Ltd., purity >=98%.Dimethyl sulfoxide (DMSO) is purchased from Sigma company.
Tetramethyl thiazole pale blue (MTT) is purchased from green skies biotechnology research institute company.
Fetal calf serum, DMEM culture medium are purchased from Gibco company.
Human ovarian carcinoma paclitaxel multidrug resistant cell line A2780/Taxol is purchased from Shanghai Mei Xuan Biotechnology Co., Ltd.
Two, experimental method
1, cell culture
With the DMEM culture medium containing 10% fetal calf serum in 37 DEG C, 5%CO2Human ovarian cancer Japanese yew is cultivated in cell incubator
Alcohol drug-resistant cell strain A2780/taxol after cell covers with culture bottle bottom 70%~80%, with pancreatin digestion, is collected, centrifugation, biography
In generation, logarithmic growth phase cell is for testing.
2, reverse effect of each compound to A2780/Taxol drug resistance
The Proliferation of Human Ovarian Cell A2780/Taxol cell for taking logarithmic phase to grow adjusts cell density, by every hole 8 × 103It is a
For cell inoculation in 96 orifice plates, every hole adds 180 μ L cell suspensions, after culture for 24 hours, final concentration of 10 μM of the shellac acid of addition,
The Taxol of jalaric acid, cypress acid or cedar wood alcohol and various concentration, final concentration is respectively 0,1,5,25,125,250 μ g/
ML, every 200 μ L of hole total volume；If control wells are that drug is not added；Zeroing hole is the culture solution that cell is not added, and every group sets 3 again
Hole.It is placed in saturated humidity, 37 DEG C, 5%CO2Continue to cultivate 48h in incubator, each hole is added MTT (5mg/mL) 10 μ L, continues to train
4h is supported, culture supernatant is discarded, every hole is added on 150 μ L shaking table of DMSO and shakes 10min, measures each hole OD570 value, calculates taxol
Inhibiting rate and IC50 value, Resistance index to A2780/Taxol cell Proliferation.
Calculation formula are as follows: inhibitory rate of cell growth (%)=[1- (experimental group OD value-blank group OD value)/(control group OD
Value-blank group OD value)] × 100%；IC50 value is calculated using 10.0 software of SigmaPlot；Drug resistance reversal fold (RI)=medicine
Cell IC50 after cell IC50/ effect before object acts on.
3, statistical method
Statistical analysis is carried out using SPSS17.0, two comparison among groups are examined using t, and P < 0.05 is that difference has statistics
Meaning.
Three, experimental result
As a result as shown in table 1 and Fig. 2, shellac acid, jalaric acid, cypress acid can enhance Taxol pairs to some extent
The inhibited proliferation of A2780/Taxol cell improves cell to the sensibility of Taxol, and cedar wood alcohol effect is unobvious.The result
Show that shellac acid, jalaric acid, cypress acid can reduce A2780/Taxol cell to the resistance of Taxol.
The reverse effect of each compounds on ovarian cancer cell A2780/Taxol drug resistance of table 1
| IC50(μg/mL) | Drug resistance reversal fold | |
| Taxol Taxol | 31.58 | / |
| Shellac acid | 3.95 | 7.99 |
| Jalaric acid | 2.77 | 11.40 |
| Cypress acid | 6.24 | 5.06 |
| Cedar wood alcohol | 29.81 | 1.06 |
To sum up, shellac acid, jalaric acid, cypress acid, which can be developed into, reverses oophoroma to the medicine of taxol resistance
Object.
The effect of above-described embodiment is specifically to introduce essentiality content of the invention, but those skilled in the art should know
Protection scope of the present invention should not be confined to the specific embodiment by road.
Claims (4)
1. application of the shellac acid in terms of the drug that preparation reverses ovarian cancer drug-resistant.
2. application according to claim 1, it is characterised in that: reverse oophoroma to taxol resistance.
3. a kind of for reversing the pharmaceutical preparation of ovarian cancer drug-resistant, it is characterised in that: active constituent is shellac acid.
4. pharmaceutical preparation according to claim 3, it is characterised in that: reverse oophoroma to taxol resistance.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811167944.2A CN109223746B (en) | 2018-10-08 | 2018-10-08 | Application of lithospermic acid in reversing drug resistance of ovarian cancer to paclitaxel |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811167944.2A CN109223746B (en) | 2018-10-08 | 2018-10-08 | Application of lithospermic acid in reversing drug resistance of ovarian cancer to paclitaxel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109223746A true CN109223746A (en) | 2019-01-18 |
| CN109223746B CN109223746B (en) | 2020-12-18 |
Family
ID=65055282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811167944.2A Active CN109223746B (en) | 2018-10-08 | 2018-10-08 | Application of lithospermic acid in reversing drug resistance of ovarian cancer to paclitaxel |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109223746B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007039421A (en) * | 2005-08-01 | 2007-02-15 | Ivy Cosmetics Corp | Skin care preparation for ameliorating roughened skin |
-
2018
- 2018-10-08 CN CN201811167944.2A patent/CN109223746B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007039421A (en) * | 2005-08-01 | 2007-02-15 | Ivy Cosmetics Corp | Skin care preparation for ameliorating roughened skin |
Non-Patent Citations (3)
| Title |
|---|
| A. N. SINGH等: "Chemistry of lac resin-II lac acids(parts 2): laccijalaric acid", 《TETRAHEDRON》 * |
| A.B.UPADHYE等: "Chemistry of lac resin-iv pure lac resin-1: isolation and quantitative determination of constituent acids", 《TETRAHEDRON》 * |
| 肖艳: "蒙成药北沙参四味汤概述", 《世界最新医学信息文摘》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109223746B (en) | 2020-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| da Costa et al. | The NFκB signaling pathway in papillomavirus-induced lesions: friend or foe? | |
| CN108913662B (en) | A kind of method of the functional high-throughput medication screening of lung cancer | |
| He et al. | Anti-cervical cancer activity of secondary metabolites of endophytic fungi from Ginkgo biloba | |
| Ngameni et al. | Antimalarial prenylated chalcones from the twigs of Dorstenia barteri var. subtriangularis | |
| CN104910196B (en) | A kind of chiral copper-based organic metal framework of four core and its preparation method and application | |
| CN106074557B (en) | D type guanine alanine is preparing the application in medicines resistant to liver cancer | |
| CN109223745A (en) | A kind of cypress acid is for reversing oophoroma to the purposes of taxol resistance | |
| CN109223746A (en) | A kind of shellac acid is for reversing oophoroma to the purposes of taxol resistance | |
| CN109260187A (en) | A kind of jalaric acid is for reversing oophoroma to the purposes of taxol resistance | |
| CN114432370A (en) | Russian fruit extract and pharmaceutical application thereof | |
| CN111803472A (en) | Novel coronavirus resistant medicine and application thereof | |
| CN114748466B (en) | Application of Napyradiomycin compounds in preparation of porcine pseudorabies virus inhibitor | |
| Nada et al. | Cytotoxic effects of Ammi visnaga volatile oil on some cancer cell lines | |
| CN108383824A (en) | A kind of benzopyrone dimer and its extracting method and application | |
| CN114831980A (en) | A composition containing wogonin and baicalein and its application in preparing medicine for treating colorectal cancer | |
| CN109833321A (en) | It is a kind of to reverse liver cancer cells to the pharmaceutical composition of sorafenib drug resistance | |
| CN103435590A (en) | Curvularin derivatives and preparation method and application thereof | |
| CN104388389B (en) | Method for establishing paclitaxel (PTX)-resistant ovarian cancer cell model | |
| CN110368386A (en) | A kind of application of oxygen-containing endocyclic compound in the drug of preparation treatment malignant tumour | |
| CN105079006A (en) | Application of aphanalide J to preparation of drugs for treating liver cancer | |
| JP2022513042A (en) | Production method and pharmaceutical composition of camphor tree extract, camphor tree composition | |
| CN103833766B (en) | Shore, Agra dimethylamine fumarate and the purposes in prepared by medicine thereof | |
| CN109730999A (en) | Thiazole benzamide it is derivative prepare anti-osteoporosis, the application in Hyanalgese-D object | |
| CN114569620B (en) | Application of agent based on tolhenone compounds in preparation of tumor treatment drugs | |
| CN107536830A (en) | Anti-hepatic fibrosis medicines composition containing diallyl disulfide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Kan kinbo Inventor after: Zhang Luyan Inventor after: Li Juanjuan Inventor after: Zheng Jiarong Inventor after: Qu Weiping Inventor after: Wan Chao Inventor before: Zheng Jiarong Inventor before: Qu Weiping Inventor before: Wan Chao |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20201130 Address after: Room 204, unit 2, building 2, No. 529, Yangcheng Fourth Road, Yangxin County, Binzhou City, Shandong Province Applicant after: Kan kinbo Address before: 223001 room 112, Han Hou Avenue, qingJiangpu District, Huaian, Jiangsu, 112 Applicant before: HUAI'AN ANLAI BIOTECHNOLOGY Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |